AUG 07, 2017 3:22 PM PDT

Midlife Prostate Screening Could Predict Future Cancer Risks

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

Prostate cancer screening remains an effective way to detect for the presence of the cancer in men. And this study suggests that it’s not just older men who need the screening – younger men need to do it too, and they may actually benefit more from earlier screenings.

Measuring the level of prostate-specific antigen (PSA) is a minimally invasive method to predict cancer risks. However, tests that use this biomarker have been criticized for its diagnostic power. PSA levels for healthy men are usually less than 4 nanograms per milliliter (ng/mL) of blood. However, having more or less PSA than that range doesn’t guarantee cancer or no cancer, respectively. Furthermore, PSA level cutoffs are not standardized, which contributes to increased cases of false negatives and false positives. As such, PSA tests can sometimes result in unnecessary biopsies.
 
Now a study reports that a single reading of PSA levels in younger men may help doctors narrow down the risks of prostate cancer in later life.   
 
"We found a single baseline PSA-level measurement during midlife could accurately predict future risk of lethal prostate cancer," said Mark Preston, a physician at Brigham and Women’s Hospital Division of Urology, and first study author "These data identify subgroups of men, based on their PSA levels at a given age, who could benefit from screening intervals tailored to their actual magnitude of risk."

 
Using data and samples from a cardiovascular study that began in 1982, the team extracted information from 234 men who were diagnosed with prostate cancer and 711 men who were healthy controls. The men were between 40 and 59 years old at the start of the trial. And with a single measure of PSA at this time point, the team said that they can accurately predict the risks of prostate cancer for the men later in life.
 
For men whose baseline PSA was above median (i.e., greater than 1.0 ng/ml) at age 40 to 49, nearly 82 percent went on to develop prostate cancer in later life. Conversely, men of 60 years old whose tests reveal PSA levels of less than the median were least likely to develop prostate cancer.
 
"These data support the recommendation that risk-stratified screening for prostate cancer based on mid-life PSA should be considered in men aged 45 to 59," said Lorelei Mucci, senior study author.
 
However, the authors are quick to point out that screening interventions should not be taken to the extreme for young men. "Our study does not imply prostate biopsy or definitive treatment is immediately required in younger men with higher PSA levels at baseline, as this could lead to over diagnosis. Rather, these men should undergo more intensive PSA screening to enable earlier identification of cancer and potential cure while still possible."
 
Prostate cancer represents a huge health risk for half the world’s population, as it is the most common form of cancer in men, second only to skin cancer. Current treatments for the disease involve radiation and chemotherapy aimed at the cancer cells in the prostate, or surgical removal of the prostate itself. For 2016, the American Cancer Society estimates over 180,000 new prostate cancer cases. Given these alarming statistics, men should not hesitate to ask their doctors for a prostate cancer screen. 


Additional source: Brigham and Women's Hospital press release

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAR 23, 2020
Cancer
MAR 23, 2020
An Alternative Use for Common Kidney Cancer Drug to Fight Against Epithelial Ovarian Cancer
Axitinib is a small molecule drug that inhibits VEGFR tyrosine kinases 1, 2, and 3. Shown previously to potentially prev ...
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native lig ...
APR 20, 2020
Cancer
APR 20, 2020
Expanding the Diagnostic Toolkit in Cancer Research with isomiRNAs
Esophageal cancers are one of the more common cancers around the world, with an unfortunately poor prognosis. The five-y ...
APR 30, 2020
Cancer
APR 30, 2020
A New microRNA for the Cancer Fighting Toolkit
MiRNAs are small snippets of genetic information that regulate gene expression thought to be able to regulate up to 60% ...
MAY 07, 2020
Cell & Molecular Biology
MAY 07, 2020
How the Function of a Critical Immune Cell is Related to Metabolism
This work suggests that it may be possible to dampen autoimmunity or promote an immune attack on cancer through a bioche ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Approved Treatment for RET-mutant Cancers
A drug was recently approved for treating three types of RET-mutant cancers: 1) non-small cell lung cancer (NSCLC) 2) ad ...
Loading Comments...